Vital Signs Podcast: Aroa Biosurgery sets sights on positive operating cash flow in H2 FY25

Vital Signs is a podcast series focused on investing, hosted by Senior Health and Biotech journalist Nadine McGrath.

In this episode Nadine chats to CFO at Aroa Biosurgery (ASX:ARX), James Agnew.

Aroa Biosurgery is a soft-tissue regeneration company committed to unlocking regenerative healing for everybody through its patented AROA ECM™ complex wound and tissue reconstruction products.

The company was founded in 2008 by Veterinarian Surgeon Dr Brian Ward, who discovered that a tissue scaffold called the extra cellular matrix (ECM) found in the forestomach of sheep has a similar structure to human tissue and contains over 150 proteins known to be important in the healing process.

ARX reported strong quarterly results with net operating cash outflow of NZ$3.6m for Q1 FY25 but forecasting to be cashflow positive in H2 FY25.

To hear Nadine and James discuss all this and more, tune in below!

Like to tune in through another app? Just search for Vital Signs with Nadine McGrath and subscribe!

This podcast was developed in collaboration with Aroa Biosurgery, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.